Champlain Investment Partners, LLC Supernus Pharmaceuticals, Inc. Transaction History

Champlain Investment Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$19.93 - $29.13 $12.5 Million - $18.2 Million	-626,040 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $24.5 Million - $32 Million	-960,085 Reduced 60.53%	626,040 $17.2 Million
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $767,275 - $995,460	25,610 Added 1.64%	1,586,125 $52.5 Million
Q1 2019 May 14, 2019	SELL	$32.77 - $41.99 $153,035 - $196,093	-4,670 Reduced 0.3%	1,560,515 $54.7 Million
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $7.23 Million - $11.6 Million	234,480 Added 17.62%	1,565,185 $52 Million
Q3 2018 Nov 13, 2018	BUY	$42.7 - $56.55 $2.67 Million - $3.53 Million	62,450 Added 4.92%	1,330,705 $67 Million
Q2 2018 Aug 13, 2018	SELL	$44.1 - $59.85 $304,290 - $412,965	-6,900 Reduced 0.54%	1,268,255 $75.9 Million
Q1 2018 May 14, 2018	BUY	$37.15 - $46.9 $2.32 Million - $2.93 Million	62,370 Added 5.14%	1,275,155 $58.4 Million
Q4 2017 Feb 12, 2018	SELL	$36.4 - $42.6 $625,716 - $732,294	-17,190 Reduced 1.4%	1,212,785 $48.3 Million
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $45.2 Million - $61.1 Million	1,229,975	1,229,975 $49.2 Million

281

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Champlain Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Champlain Investment Partners, LLC with notifications on news.